A Study to Evaluate the Efficacy and Safety of AD-218

A Randomized, Double-blinded, Active-controlled, Multicenter Phase 3 Clinical Trial and Open-label, Extension Study to Evaluate the Efficacy and Safety of AD-218 in Patients with Mixed Dyslipidemia

The purpose of this study is to evaluate the efficacy and safety of AD-218

Condition or disease : Mixed Dyslipidemia Treatment Drug : AD-218, AD-218A, Placebo of AD-218, Placebo of AD-218A

Inclusion Criteria:

• A man or woman over 19 years old.
• Sign on ICF prior to study participation

Exclusion Criteria:

• History of Fibromyalgia, Myopathy etc (CK ≥ 2 X ULN)
• Other exclusions applied